Analyst consensus rating
NervGen Pharma Analyst Rating: none
Direct answer
NervGen Pharma's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.00.
Forecast evidence checked September 5, 2026.
Get free NervGen Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.33
- Average price target
- $10.00
- High price target
- $10.00
- Low price target
- $10.00
- Low target gap
- +329.2%
- Target upside
- +329.2%
- High target gap
- +329.2%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for NervGen Pharma?
NervGen Pharma has a verified none consensus. The same dataset has an average price target of $10.00.
How far are NervGen Pharma's low and high targets from the recorded price?
The low target implies +329.2%, while the high target implies +329.2%.
How many analysts are included in NervGen Pharma's consensus?
The verified consensus includes 1 analysts.
How is NervGen Pharma's target upside or downside calculated?
The average target of $10.00 is divided by the recorded price of $2.33, then one is subtracted to produce +329.2%. This does not guarantee a future return.
When was NervGen Pharma's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.